Trial Profile
A Phase I Study of the Safety, Pharmacokinetic and Pharmacodynamic Properties of Orally Administered APG-115 in Patients With Advanced Solid Tumors or Lymphomas
Status:
Active, no longer recruiting
Phase of Trial:
Phase I
Latest Information Update: 13 Jan 2022
Price :
$35
*
At a glance
- Drugs Alrizomadlin (Primary)
- Indications Brain metastases; Lymphoma; Solid tumours
- Focus Adverse reactions
- Sponsors Ascentage Pharma
- 21 Apr 2020 Status changed from recruiting to active, no longer recruiting.
- 04 Jun 2019 Results (n=28) presented at the 55th Annual Meeting of the American Society of Clinical Oncology
- 03 Jun 2019 Results published in the Ascentage Pharma Media Release